Brimonidine Tartrate and Timolol Maleate

BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

Manufacturer: Somerset Therapeutics, LLC

Score: 141.86

Quick Summary

Brimonidine tartrate and Timolol maleate ophthalmic solution is used for the reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension. The recommended dose is one drop in the affected eye(s) twice daily, approximately 12 hours apart. The solution contains 2 mg/mL brimonidine tartrate and 5 mg/mL timolol. It is contraindicated in patients with bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, atrioventricular block, overt cardiac failure, cardiogenic shock, and in neonates and infants under the age of 2 years. The most common adverse reactions include allergic conjunctivitis, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, ocular burning, and stinging.

Key Clinical Findings and Indications

Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension
Decreases intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow

Important Safety Information

Warning

Brimonidine tartrate and Timolol maleate ophthalmic solution may cause systemic beta-blockade, and caution should be exercised when using it in patients with cardiovascular disease.

Contraindications

Bronchial asthma
Severe chronic obstructive pulmonary disease
Sinus bradycardia
Atrioventricular block
Overt cardiac failure
Cardiogenic shock
Neonates and infants under the age of 2 years

Adverse Reactions

Allergic conjunctivitis
Conjunctival folliculosis
Conjunctival hyperemia
Eye pruritus
Ocular burning
Stinging

Dosing Recommendations

General Guidance

None specified

Glaucoma or ocular hypertension

Adult Dose

One drop in the affected eye(s) twice daily, approximately 12 hours apart

Pediatric Dose

Not recommended for children under the age of 2 years

Special Population Considerations

Pregnancy

Brimonidine tartrate and Timolol maleate ophthalmic solution should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus

Nursing Mothers

Timolol has been detected in human milk, and it is not known whether brimonidine tartrate is excreted in human milk

Pediatric Use

Brimonidine tartrate and Timolol maleate ophthalmic solution is contraindicated in children under the age of 2 years
The safety and effectiveness of brimonidine tartrate and timolol maleate have not been studied in children below the age of 2 years